Find Funding Opportunities

The National Institute of Neurological Disorders and Stroke (NINDS) invites cooperative agreement applications from qualified institutions for support of a Parkinsons Disease Data Organizing Center (PD-DOC), designed to serve as a shared research resource to facilitate research in Parkinsons disease (PD). This resource is intended to compile clinical data, as well as to provide virtual catalogues for both basic scientific and clinical research in PD. Parkinsons disease research would benefit from analysis of combined data collected systematically from existing PD Centers (Udall Centers, NIEHS centers, NIA Alzheimers Disease Centers) and, eventually, from other sources where longitudinal data are collected. Such data on patients and unaffected, age-matched controls would support 1) clinical, molecular and pathological research on disease natural history, heterogeneity, diagnosis, and clinical-pathological correlations; and 2) epidemiological research related to the identification of risk factors, neuroprotective factors or biomarkers. As clinical components are built into the Morris K. Udall Parkinsons disease Centers of Excellence and other PD Centers, the advance funding of this data coordination initiative will function to systematize data collection and analysis across centers. In addition, existing databases should be assessed as to their relevancy and incorporation into this national resource. Data from all PD center resources can thus be combined, coordinated, and made available to researchers from PD centers as well as the wider PD research community. The primary objectives will be to: 1) Establish, maintain, and disseminate a data base of clinical, pathological and biochemical information collected at Udall Centers, Collaborative Centers for Parkinsons Disease Research (CCPDER), or other PD centers, from persons with Parkinsons disease and related disorders and from unaffected age-matched controls; 2) Assess availability and potential use of existing databases and how they could be incorporated or made compatible, as well as provide training and data quality control across all participating sites. 3) Provide assistance to investigators in planning and conducting research studies using the database; 4) Make available virtual data and a catalog of tissues and other biological samples collected from PD patients and controls for use in epidemiological, clinical, molecular and pathological studies by qualified investigators, and 5) Coordinate annual meetings of its steering committee and the annual Udall (and other) PD Centers meeting to discuss progress and collaborations. With the establishment of this data coordinating center, important and novel research issues can be addressed which would not be possible with the individual resources available at any one individual center. Research activities that use PD-DOC resources may be supported through the usual National Institutes of Health (NIH) and other federal and non-federal sources for the funding of investigator-initiated applications.

The National Institute of Dental and Craniofacial Research (NIDCR), along with the National Institute of Neurological Disorders and Stroke (NINDS), invites applications to stimulate and support innovative, interdisciplinary research studies to elucidate the molecular mechanisms underlying orofacial pain, particularly the discovery of proteins and protein networks critical to processing nociceptive information. The purpose of this RFA is to encourage the use of genomic and proteomic approaches and imaging techniques to clarify the molecular events involved in: 1) acute orofacial pain, 2) the transition from unrelieved acute pain to chronic pain (i.e. neuroplasticity), 3) neuronal hyperexcitability as manifested by hyperalgesia and allodynia, and 4) chronic orofacial pain disorders of an inflammatory and neuropathic origin. This improved understanding could lead to new therapeutic interventions to effectively treat chronic pain conditions. Collaborative projects involving interdisciplinary teams of investigators are strongly encouraged. This Request for Applications contributes to the goals of the NIH Pain Consortium, which is co- chaired by NIDCR, NINDS, and the National Institute of Nursing Research (NINR).

Participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic, applied, and translational multi- disciplinary research that addresses important biological or medical research problems. In the context of this program, a partnership is a multi- disciplinary research team that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. The partnership must include appropriate bioengineering or allied quantitative sciences in combination with biomedical and/or clinical components. The Principal Investigator (PI) also serves as the project manager and must be capable of leading the proposed effort. A BRP may propose design-directed, developmental, discovery-driven, or hypothesis-driven research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities or combinations of these entities. It is expected that a BRP will have a well-defined goal or deliverable that will be achieved based on objective milestones specified in the initial application. On October 11, 2001, the NIH issued a related program announcement (PA) PA-02-011 (http://grants.nih.gov/grants/guide/pa-files/PA-02-011.html) for Bioengineering Research Grants (BRGs). The BRGs differ from the BRPs in that the research will be performed in a single laboratory, by a single investigator, or by a small group of investigators. On January 16, 2003, the NIH issued another related program announcement PA-03-058 (http://grants.nih.gov/grants/guide/pa-files/PA-03-058.html) for Exploratory/Developmental (R21) Bioengineering Research Grants (EBRG). The EBRGs differ from the BRPs in that (1) the research will be performed in a single laboratory, by a single investigator, or by a small group of investigators and (2) the projects are high-risk/high-payoff in nature (R21 mechanism) as compared to the R01-type grants supported by the BRP program.

The National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) invite investigator-initiated research applications for mechanistic studies in clinical trials of: (1) immunomodulatory interventions for immune system mediated diseases, including, but not limited to: asthma and allergic diseases; graft failure in solid organ, cell, tissue and stem cell transplantation; and chronic inflammatory, autoimmune, and immunodeficiency diseases; and (2) preventative and therapeutic, vaccines for non-HIV/AIDS infectious diseases, including NIAID Category A, B, and C agents of bioterrorism and emerging/re-emerging infectious diseases. This Request for Applications (RFA) is a continuation and modification of RFA AI-02-003 (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-02-003.html ). In order to review and confer awards to grant applications received in response to this RFA in a timely fashion, without delay of the parent clinical trial, NIAID has developed a pilot project in collaboration with the NIH Center for Scientific Review (CSR): NIAID/CSR PILOT OF HYPERACCELERATED REVIEW/AWARD. All applications responding to this RFA will be subject to this hyperaccelerated review/award process. Highly meritorious applications selected for funding under this RFA will receive their awards thirteen weeks after the application receipt date. Holidays and other circumstances may alter this schedule slightly.

The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Deafness and Other Communication Disorders (NIDCD) invite qualified investigators to submit grant applications for the establishment of National Centers for Neurofibromatosis Research. Recent discoveries have created important opportunities for basic, translational, and clinical research on the neurofibromatoses. The purpose of this Program Announcement (PA) is to encourage the formation and development of research centers that can capitalize on these opportunities, and ultimately develop therapeutic interventions for neurofibromatosis patients. These centers are intended to provide focused expertise and resources, and establish a multi-disciplinary environment that will accelerate research progress.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Child Health and Human Development (NICHD) encourage the scientific community to use proteomics technologies to study type 1 diabetes (T1D) and its complications. Proteomic technologies have been successfully used for the identification of cancer biomarkers, for the identification of novel drug targets and for studying several biological processes relevant to human health. High throughput metabolic profiling has been recently implemented for metabolomic studies. However, as of today these technologies have been applied to study T1D and its complication only in a limited way. Moreover, currently available proteomic and metabolomic technologies represent a great opportunity for advancing the field of T1D and its complications. This RFA intends to promote the use of these technologies to study T1D and its complications emphasizing the importance of collaborative efforts between investigators with expertise in proteomics or metabolomics and investigators with expertise in T1D.

The purpose of the NIH Clinical Trial Planning Grant (R34) is to provide support for the development of a Phase III clinical trial, including the establishment of the research team, the development of tools for data management and oversight of the research, the definition of recruitment strategies, and the finalization of the protocol and other essential elements of the study included in a manual of operations/procedures. The Clinical Trial Planning Grant is not designed for the collection of preliminary data or the conduct of pilot studies to support the rationale for a clinical trial. An NIH-defined Phase III clinical trial is a broadly based prospective clinical investigation, usually involving several hundred or more human subjects, for the purpose of evaluating an experimental intervention in comparison with a standard or control intervention or comparing two or more existing treatments. Often, the aim of such investigation is to provide evidence leading to a scientific basis for consideration of a change in health policy or standard of care. The definition includes pharmacologic, non-pharmacologic, and behavioral interventions for disease prevention, prophylaxis, diagnosis or therapy. Community- and other population-based intervention trials also are included. The planning grant is designed to permit early peer review of the rationale and design of the proposed clinical trial and to provide support for the development of a detailed Manual of Procedures (MOP) including all elements essential to the launching of a trial. Investigators wishing to apply for an R34 grant should be aware that individual ICs may have specific requirements for this funding mechanism and, therefore, should consult IC staff to determine if an application is appropriate. NIH Offices that participate in this PA (ORWH, OBSSR, ORD, ODS) are listed but do not have funding authority and must work through an Institute or Center.

This Program Announcement replaces PA-02-003. The purpose of this Program Announcement (PA) is to encourage submission of new research project grant (R01) and exploratory/developmental grant (R21) applications to research and develop innovative technologies, methodologies, or instrumentation for basic or clinical studies of the brain or behavior in human or non-human animals. Also solicited are applications for support to research, develop, and significantly enhance existing technologies that are important to understanding the brain or behavior.

This Program Announcement (PA) provides updated guidelines for National Institutes of Health (NIH) support of scientific meetings. It replaces the previous guidelines issued in the NIH GUIDE on October 30, 1998, http://grants.nih.gov/grants/guide/notice-files/not98-151.html and is effective with the December 15th receipt date for cycle III applications. An NIH Conference Grant Website has been created to centralize information regarding grants for scientific meetings and conferences, at http://grants1.nih.gov/grants/funding/r13/index.htm. This site includes contact information for the participating NIH Institutes and Centers and Offices and links to detailed information regarding specific interests and funding parameters. This site and related links is updated frequently and interested parties should check periodically for the most current information. A major revision made in this announcement is the requirement that applications for conference grant support present a letter from the appropriate NIH Institute/Center (IC) staff documenting advance permission to submit an R13 or U13 application. As a streamlining measure, there are now three annual receipt dates for all applications for support of scientific meetings, and decisions about awards will normally be made within six months of submission.

This PAR replaces PAR-01-119. The NINDS is committed to identifying effective treatments for neurological disorders by supporting well-executed clinical trials. Before a definitive clinical trial can be designed, preliminary clinical studies are often required. The NINDS announces its interest in supporting studies required to obtain necessary information to establish clearly the clinical basis for proceeding to a definitive trial. The purpose of the PRELIMINARY INVESTIGATIONS LEADING TO OPTIMAL TRIALS IN NEUROLOGY grant (for brevity referred to as NINDS Preliminary Clinical Trials grant) is to obtain preliminary data and conduct studies to support the rationale for a subsequent definitive clinical trial of an intervention to treat or prevent neurological disease.